Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Related Questions
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
What is your approach to management of patients with recurrent nephrolithiasis and osteoporosis who are receiving teriparatide?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
How do you approach management of osteoporosis in patients post lung transplant?
Would you consider PTH analogue in a patient with mildly elevated PTH?
What range of musculoskeletal complaints have you seen with romosozumab use?
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
